U.S. Markets open in 5 hrs 53 mins
  • S&P Futures

    +14.50 (+0.34%)
  • Dow Futures

    +100.00 (+0.30%)
  • Nasdaq Futures

    +51.75 (+0.39%)
  • Russell 2000 Futures

    +9.20 (+0.47%)
  • Crude Oil

    -0.07 (-0.07%)
  • Gold

    +1.00 (+0.06%)
  • Silver

    +0.03 (+0.13%)

    -0.0017 (-0.1649%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +0.54 (+2.74%)

    -0.0012 (-0.1012%)

    +0.3830 (+0.2880%)

    -699.51 (-2.84%)
  • CMC Crypto 200

    -5.88 (-1.02%)
  • FTSE 100

    +12.66 (+0.17%)
  • Nikkei 225

    +727.65 (+2.62%)

Genomic Vision: Financial Information for the First Half of 2022

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Revenue up 9.4%

  • Revenues from activity up 5.8%

  • Cash at June 30, 2022 at €1.0m

BAGNEUX, France, July 22, 2022--(BUSINESS WIRE)--Regulatory News:

Genomic Vision (FR0011799907 - GV, PEA-PME eligible) (Paris:GV), a biotechnology company developing tools and services dedicated to the analysis and control of genome modifications, today announced its first half revenues and cash position at June 30, 2022.

H1 2022 (unaudited figures)

In € thousands - IFRS data

H1 2022

H1 2021

Revenue from sales



Other revenue



Total revenue from activity



Revenue from sales for the first half of 2022 amounted to €511 thousand, up 9.4% compared to the first half of 2021. This increase in sales of products and services reflects the efforts made in commercial prospecting. It should be noted that no platform sales were made during the first half of the year.

Total revenue from activity in the first half of 2022, after taking into account other revenue, is up by 5.8% compared to the same period in 2021. Other income, amounting to €232 thousand in the first half of 2022, corresponds to the research tax credit.

Financial structure at June 30, 2022

Genomic Vision had a cash position of €1.0 million at June 30, 2022, compared to €1.3 million at March 31, 2022. This decline is linked to the delay in the implementation of the new financing agreement with Winance signed on April 11, 2022 and ratified by the extraordinary general meeting of May 23, 2022.

The new financing line, now implemented, corresponds to a maximum of 15 tranches of €2 million nominal value each, i.e. up to €30 million. It will cover additional working capital requirements to support Genomic Vision's commercial development over the next three years.

Upcoming financial publications

  • H1 2022 results: Thursday, September 29, 2022

  • Q3 2022 revenue: Thursday, October 27, 2022



GENOMIC VISION is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed to high confidence characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Genomic Vision, based near Paris in Bagneux, is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For further information, please visit www.genomicvision.com


Member of the CAC® Mid & Small and CAC® All-Tradable indexes


This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the "Risk Factors" section of the universal registration document filed with the AMF on April 14, 2022 under reference number R.22-0293, as updated by the amendment filed with the AMF on May 20, 2022, under number D.22-0293-A01, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220722005399/en/


Genomic Vision
Aaron Bensimon
Tel.: +33 1 49 08 07 51

Ulysse Communication
Press Relations
Bruno Arabian
Tel.: +33 1 42 68 29 70

Investor Relations
& Strategic Communications
Tel.: +33 1 44 71 94 94